Researchers at Stanford University, in collaboration with scientists at the German Cancer Institute, have shown for the first time that shortwave infrared (SWIR) imaging can be used to visualize injectable filler materials during injection laryngoplasty, a common procedure used to treat vocal fold paralysis and other forms of glottic insufficiency. The findings, published in Otolaryngology–Head and Neck Surgery, of this novel visualization technique could pave the way for precision-guided techniques in laryngeal surgery.

An international team of researchers from Trinity College Dublin and the Moffitt Cancer Center in the US has demonstrated a landmark “evolutionary double-bind” strategy to overcome treatment resistance in prostate cancer. 

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance to currently available therapies. As a result, resistant cells eventually proliferate causing the tumour to recur, leading to treatment failure and ultimately patient death. 

In other words, increasingly the proximate cause of death in cancer patients is evolution, which sees the cancer cells adapt and overcome even highly effective treatments.

The new work found that when cancer cells successfully evolve resistance to DNA damaging treatments, they expose a critical weakness that makes them highly vulnerable to immunotherapy. This represents an “evolutionary double-bind” in which the cancer cell adaptation to one therapy makes them more vulnerable to another therapy and vice-versa.

U.S. counties located closer to operational nuclear power plants (NPPs) have higher rates of cancer mortality than those located farther away, according to a new study led by Harvard T.H. Chan School of Public Health. The study is the first of the 21st century to analyze proximity to NPPs and cancer mortality across all NPPs and every U.S. county. The researchers emphasized that the findings are not enough to establish causality but do highlight the need for further research into nuclear power’s health impacts.

In a study of adults with cancer published by Wiley online in CANCER, those who developed a mental health condition within the first year after their cancer diagnosis had a higher likelihood of dying over the next few years.

Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer. Winners will be recognised across three award categories: Platinum (40,000 euros), Gold (20,000 euros), and Silver (10,000 euros) awards. 

A new study led by City St George's, University of London provides hope that smarter timing of cancer treatments could improve cure rates.

The standard clinical approach is to wait and see if a tumour regrows before trying a different treatment. By this point, some tumour cells are likely to have gained mutations making them resistant to the second treatment, which then also fails.

Evolutionary theory suggests an alternative strategy. Instead of waiting, it might be better to switch to a second treatment while the tumour is still responding to the first one.

A study by FAPESP-supported center used the NK-92 cell line to test new chimeric antigen receptor (CAR) models. Tests demonstrated an increased ability of the cells to destroy tumors.CAR-based cell therapies are revolutionizing the treatment of tumors, especially hematological ones.